Clinical Trials

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT06925737 2026-03-13

MK-2400-001

Phase 3 Recruiting

1,440 enrolled

Prostatic Neoplasms

NCT06136650 2026-03-09

MK-5684-004

Phase 3 Recruiting

1,314 enrolled

Prostatic Neoplasms

NCT07005154 2026-03-03

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2 Recruiting

218 enrolled

Prostatic Neoplasms

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Prostatic Neoplasms

NCT07339267 2026-02-18

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Phase 1 Recruiting

12 enrolled

Prostatic Neoplasms

NCT02257736 2026-02-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 1 Recruiting

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Phase 1/2 Recruiting

100 enrolled

Prostatic Neoplasms

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT02960022 2025-12-17

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2 Recruiting

900 enrolled

Prostatic Neoplasms

NCT06689163 2025-09-03

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Phase 1/2 Recruiting

66 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT03348670 2025-08-17

Drugs-SNPs

600 enrolled

Neoplasms, Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03072238 2025-06-06

IPATential150

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Phase 2/3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03706365 2025-04-20

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT04556617 2025-04-08

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

19 enrolled 11 charts

Adenocarcinoma, Prostatic Neoplasms

NCT01792687 2025-03-04

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

6 enrolled

Prostatic Neoplasms

NCT02043678 2025-02-19

ERA 223

806 enrolled 32 charts

Prostatic Neoplasms

NCT00887198 2025-02-04

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

1,088 enrolled 14 charts

Prostatic Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT04291664 2024-10-17

PK and Dose Escalation and Expansion Study of DST-2970

Phase 1 Terminated

26 enrolled

Prostatic Neoplasms

NCT06554639 2024-10-15

MK-5684-011

12 enrolled

Prostatic Neoplasms

NCT01685268 2024-08-02

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Phase 1/2 Completed

49 enrolled

Prostatic Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04887506 2024-01-16

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

107 enrolled 20 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

158 enrolled 32 charts

Prostatic Neoplasms

NCT01995513 2023-09-18

PLATO

Phase 4 Completed

509 enrolled 18 charts

Prostatic Neoplasms

NCT04628988 2023-09-13

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT00350051 2021-04-08

ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer

53 enrolled

Prostatic Neoplasms

NCT00466440 2020-11-06

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

108 enrolled 22 charts

Prostatic Neoplasms

NCT02924766 2020-07-20

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

34 enrolled

Prostatic Neoplasms

NCT01591122 2020-01-21

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

313 enrolled

Prostatic Neoplasms

NCT02344017 2019-12-19

DUALIDES

Phase 1/2 Completed

23 enrolled

Prostatic Neoplasms

NCT01204710 2019-09-20

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

123 enrolled 21 charts

Prostatic Neoplasms

NCT01084655 2019-07-30

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

38 enrolled 29 charts

Prostatic Neoplasms

NCT02034552 2019-07-23

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

68 enrolled 17 charts

Prostatic Neoplasms

NCT01695135 2019-07-18

A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

214 enrolled 16 charts

Prostatic Neoplasms

NCT01867710 2019-07-05

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

164 enrolled 22 charts

Hyperaldosteronism, Prostatic Neoplasms

NCT01308567 2019-06-05

FIRSTANA

1,168 enrolled 17 charts

Prostatic Neoplasms

NCT00642018 2019-04-03

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

154 enrolled 20 charts

Prostatic Neoplasms

NCT01193257 2018-12-19

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

1,099 enrolled 32 charts